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Abstract
Vitamin D receptor (VDR) is a substrate for modification with small ubiquitin-like modifier (SUMO). To further assess the role
of reversible SUMOylation within the vitamin D hormonal response, we evaluated the effects of sentrin/SUMO-specific
proteases (SENPs) that can function to remove small ubiquitin-like modifier (SUMO) from target proteins upon the activities
of VDR and related receptors. We report that SENP1 and SENP2 strikingly potentiate ligand-mediated transactivation of VDR
and also its heterodimeric partner, retinoid X receptor (RXRa) with depletion of cellular SENP1 significantly diminishing the
hormonal responsiveness of the endogenous vitamin D target gene CYP24A1. We find that SENP-directed modulation of
VDR activity is cell line-dependent, achieving potent modulatory effects in Caco-2 and HEK-293 cells, while in MCF-7 cells
the vitamin D signal is unaffected by any tested SENP. In support of their function as novel modulators of the vitamin D
hormonal pathway we demonstrate that both SENP1 and SENP2 can interact with VDR and reverse its modification with
SUMO2. In a preliminary analysis we identify lysine 91, a residue known to be critical for formation and DNA binding of the
VDR-RXR heterodimer, as a minor SUMO acceptor site within VDR. In combination, our results support a repressor function
for SUMOylation of VDR and reveal SENPs as a novel class of VDR/RXR co-regulatory protein that significantly modulate the
vitamin D response and which could also have important impact upon the functionality of both RXR-containing homo and
heterodimers.
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Introduction
The small ubiquitin-related modifier (SUMO) represents a
novel class of ubiquitin-like protein that has emerged over the past
decade as a key regulator of cellular protein activity [1]. In
contrast to ubiquitination which results primarily in substrate
degradation, conjugation with SUMO can alter the properties of
the target protein in a variety of ways, including its profile of
localization, interactions, and susceptibility to alternate modifica-
tion processes [2]. The current list of known SUMOylated
substrates is represented primarily (although not exclusively) by
nuclear proteins, the modifications of which establish SUMOyla-
tion as a process integral to gene expression, nuclear body
formation and the maintenance of genomic/chromosomal stabil-
ity. In addition, there is accumulating evidence that link SUMO-
related events to certain cancers as well as neurodegenerative
disorders such as Alzheimer’s and Parkinson’s disease [3–6]. As
common to many regulatory mechanisms, the conjugation of a
target substrate with SUMO can be reversed, a process facilitated
through the activities of a family of sentrin/SUMO-specific
proteases (SENPs) [7]. While the human genome is thought to
encode approximately 100 enzymes of a putative deubiquitination
function [8], there are in contrast only six known members of the
mammalian SENP family that differ from each other through their
patterns of expression, subcellular localization, SUMO paralog
specificity, and predominant reaction catalyzed among the events
of SUMO processing, deconjugation or chain-editing [9,10].
Although it remains to be determined as to how a large number of
SUMOylated proteins may be selectively processed through a
comparatively limited number of SENPs, it would appear that
these proteases do not exhibit redundant or overlapping enzymatic
activities but rather exert their biological effects in a precise
manner [11].
Several members of the superfamily of nuclear hormone
receptors (NHRs), including the steroid receptors for androgen
(AR), estrogen (ER) in addition to ‘metabolic-sensors’ such as liver
X receptor a (LXRa), pregnane X receptor (PXR) and
peroxisome proliferator-activated receptor c (PPARc) are known
to be directly SUMOylated with this modification having
significant impact upon their function as transcriptional activators
or transrepressors [12–17]. NHR-directed regulation of gene
expression involves their recruitment of protein metacomplexes to
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the target gene promoter that dictate chromatin accessibility and
serve as molecular bridges with the basal transcriptional machin-
ery. As a number of receptor interacting proteins within these
complexes, such as steroid receptor coactivator-1 (SRC-1),
glucocortocoids receptor-interacting protein-1 (GRIP1), and his-
tone deacetylase-1 (HDAC1), are known to be SUMOylated [18–
20], it is clear that conjugation with SUMO and its subsequent
reversal through SENP activity can potentially modulate NHR-
mediated signaling at several key regulatory points and may
represent a means for achieving subtle differential cell and gene
specific responses to receptor stimuli.
We recently reported vitamin D receptor (VDR) to be a
SUMOylated protein, a process enhanced through interaction
with protein inhibitor activated STAT 4 (PIAS4) which also serves
as a potent inhibitor of the transcriptional response to
1,25(OH)2D3 (1,25D) [21]. As our data associate VDR SUMOy-
lation with repressed level of receptor transactivation, we
employed a series of functional assays to assess the impact of
SENP co-expression upon the activities of VDR in relation to
effects achieved with other members of the heterodimerizing class
of receptor. Our data reveal that SENP1 and SENP2 have the
capacity to directly associate with VDR and serve as novel cell-
type and potentially gene-specific modulators of the 1,25D
response. Intriguingly both SENP1 and SENP2 facilitate the
removal of SUMO2 from modified VDR. Our data implicate that
SUMOylation of VDR and its reversal through SENP-mediated
activity may represent a means to achieve ‘fine-tuning’ of the
cellular responses to dietary and endocrine-derived ligands for
VDR.
Materials and Methods
Cell Culture and Ligands
HEK-293, CHO-K1 and MCF-7 cells were obtained from the
European Collection of Cell Culture (ECACC). Caco-2 cells were
purchased from American Tissue Culture Collection (ATCC). All
cells were cultured in a 37uC incubator with 5% CO2 with all
media and supplements obtained from GIBCO (Invitrogen,
Carlsbad, CA), unless otherwise stated. The standard culturing
conditions for each cell line and passage number when used were:
HEK-293 (p71–82) Dulbecco’s modified eagle medium (DMEM)
+10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 units/ml
penicillin G and 50 mg/ml streptomycin; CHO KI (p15–20)
DMEM-F12+10% FBS, 2 mM L-glutamine, 50 units/ml penicil-
lin G and 50 mg/ml streptomycin; MCF-7 (p22–26) DMEM +
10% FBS, 1% L-Glutamine, and 1% non-essential amino acids;
Caco-2 (p22–29) DMEM containing high glucose (Sigma, St.
Louis, MO) +15% FBS.
The ligands for VDR (1,25(OH)2D3), RXRa (9-cis retinoic
acid), LXRa (TO901317) and PPARc (GW1929) were all
purchased from Sigma. The FXR ligand GW474066 was a
generous gift of Dr. Stacey Jones, Glaxosmithkline, Research
Triangle Park, North Carolina.
Plasmids
Expression plasmids for full length human VDR and RXRa
(pSG5hVDR and pSG5hRXRa, respectively) were kindly pro-
vided by Prof Mark Haussler, University of Arizona, College of
Medicine, Phoenix. The construct pcDNAV5-VDR that encodes
human VDR ‘tagged’ with the V5 epitope has been previously
described [21]. Expression vectors for human SENP1 (pFLAG-
CMV-SENP1) and SENP2 (pFLAG-CMV-SENP2) were a
generous gift from Prof. Edward T. H. Yeh of University of
Texas M. D. Anderson Cancer Center. ‘Entry’ clones encoding
full length human VDR and RXRa, in addition to the ligand
binding domains (LBD) of human VDR (aa96–427), hRXRa
(aa197–462), LXRa (aa104–447) FXR (aa156–472), and PPARc
(aa166–477) were initially generated via PCR from a human fetal
brain cDNA library, followed by insertion of each purified DNA
fragment into the pDONR201 vector via ‘BP clonase’ reaction
(Invitrogen). Entry clones for SENP1 and 2 were similarly
produced using products amplified from their respective expres-
sion vectors as template. Gal4-based hybrid expression vectors for
each nuclear receptor and SENP evaluated were then obtained
through the ‘LR clonase’ reaction using the appropriate entry
clone combined with either of the mammalian hybrid expression
vectors pCMVBD or pCMVAD (Stratagene, La Jolla, CA),
previously modified to be gateway compatible. All constructs were
subjected to DNA sequencing to confirm correct identity and
reading frame for each gene insert. Vectors expressing Ubc9 and
His-tagged SUMO2 have been previously described [21]. The
firefly luciferase-based reporter construct pMCS-24OHase con-
tained a 5500 bp fragment of the promoter region from the
human vitamin D3 24 hydroxylase (CYP24A1) gene. For experi-
ments based upon the activities of Gal4DBD-nuclear receptor
hybrid proteins, the transcriptional responses to cognate ligand
were monitored through the luciferase signal generated from the
pFLUC reporter (Stratagene) that contains five copies of the Gal4
response element.
Site-Directed Mutagenesis
Synthesis of point mutations within the pcDNAV5-VDR and
Gal4-based expression constructs for VDR was accomplished
through the Quikchange XL site-directed mutagenesis system
(Agilent Technologies) using the following mutagenic primer pairs;
K91RVDR.
59-CATCGGCATGATGAGGGAGTTCATTCTGAC-39
59-GTCAGAATGAACTCCCTCATCATGCCGATG-39
K103RVDR.
59-GAAGTGCAGAGGAGGCGGGAGATGATCC-39
59-GGATCATCTCCCGCCTCCTCTGCACTTC-39
K111RVDR.
59-GATCCTGAAGCGGAGGGAGGAGGAGGCC-39
59-GGCCTCCTCCTCCCTCCGCTTCAGGATC-39
K399RVDR.
59-CAATGAGGAGCACTCCAGACAG-
TACCGCTGCCTCTC-39
59-GAGAGGCAGCGGTACTGTCTGGAGTGCTCCT-
CATTG-39
K413RVDR.
59-GAGTGCAGCATGAGGCTAACGCCCCTTG-39
59-CAAGGGGCGTTAGCCTCATGCTGCACTC-39
Transcriptional Activation Assays
Cultured cells were trypsinized at ,80% confluency and then
seeded unto a 96-well plate at 16104 cells/well (for CHO-K1) or a
24-well plate at 2–36105 cells/well (for all other cell types). All
cells were seeded in their standard culture media with the
exception of MCF-7 cells where phenol red free DMEM
supplemented with 5% charcoal stripped FBS was used (plus L-
glutamine and NEAAs). After an incubation period of 24 hours,
cells were subsequently transfected with the appropriate combi-
nations of plasmid via Lipofectamine 2000 following a protocol
based on manufacturer’s instructions. Reporter activity was
measured following lysis of cells in passive lysis buffer (Promega)
and recording of chemiluminescent signal through use of the Dual-
Glo Luciferase Reporter Assay System (Promega). Transfection
data was normalized relative to the luciferase signal produced from
SENPs as Modulators of VDR Activity
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the constitutively active renilla vector (pRL-TK) and expressed as
a mean of relative light units from triplicate assays 6 the standard
deviations.
Protein-protein Interaction Experiments
Association between SENP and VDR or RXRa proteins were
assessed through both mammalian two hybrid and GST-pulldown
methodologies. Two hybrid experiments were performed using
CHO-K1 cells under standard culturing conditions. Co-transfec-
tion of CHO-K1 cells with the appropriate bait (SENP) and prey
(receptor) fusion constructs, in combination with the reporter
pFLUC and pRL-TK internal control, were performed using
Lipofectamine 2000 based protocol and reporter activity measured
using the Dual-Glo luciferase system as described above.
pDEST17 plasmids containing cDNA inserts for either SENP1
or 2 were produced through LR clonase reaction and together
with the pSG5hRXRa expression construct, were used as
templates in an in vitro transcription/translation (IVTT) reaction
(Promega Corp) to generate [35S]-methionine-labeled SENP and
hRXRa proteins. GST-hVDR fusion protein, or GST alone,
bound to glutathione-coated Sepharose beads were generated as
previously described [22]. All beads were then pre-incubated with
1026 M 1,25D or ethanol vehicle for 1 h at 22uC, followed by
incubation with 20 ml of the appropriate radiolabeled IVTT lysate
for 1 h at 4uC. The beads were then washed extensively as detailed
by Jurutka and co-workers [22] and the amount of co-precipitated
SENPs or hRXRa detected by electrophoresis of denatured bead
samples followed by autoradiography.
Western Blotting
Whole cell extracts from treated cells was achieved using a
RIPA buffer (50 mM Tris HCl pH7.5, 150 mM NaCl, 0.5%
IGEPAL, 5 mM EDTA pH8.0 and 10% glycerol). Samples were
added to a 4X loading buffer (200 mmol/L Tris HCl pH 6.8,
400 mmol/L b-mercaptoethanol, 8% SDS, 0.4% bromophenol
blue and 40% glycerol), heated at 95uC for 5 min and 50 mg of
each lysate then fractionated through SDS-PAGE electrophoresis
on a 4–12% NuPAGE Bis/Tris gel (Invitrogen). After transfer
onto an Immobilon-P membrane (Millipore Corp, Billerica, MA),
target or ‘tagged’ proteins were detected using the following
antibodies: rat monoclonal (9A7) anti-human VDR (Enzo Life
Sciences) at a 1:5000 dilution; rabbit polyclonal anti-Gal4 DBD
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:1000
dilution; mouse monoclonal anti-V5 (Invitrogen) at a 1:5000
dilution; mouse, mouse monoclonal anti-6xHis (Abcam) at 1:1000
dilution; mouse monclonal anti-Flag (Sigma) at a 1:1000 and
mouse monoclonal anti b-actin (Sigma) at 1:10000 dilution.
Proteins were visualized using Supersignal West Pico Chemilumi-
nescent solution (Thermo Scientific) and development on autora-
diographic film, on a Kodak X-Omat 1000 processor. Following
stripping and blocking, all membranes were re-probed with a
mouse monoclonal anti-b-actin antibody (Sigma) at 1:10,000
dilution. The secondary antibody used was a rabbit anti-mouse
IgG (whole molecule) peroxidase conjugate antibody (Sigma) and
the membrane was processed and developed as described above.
mRNA Expression Analysis through PCR, qRT-PCR and
siRNA Approaches
For studies of the effects of SENP1 over-expression upon
endogenous CYP24A1 gene transcription, Caco-2 cells were plated
at 16106 cells/60 mm plate and co-transfected with pSG5hVDR
in combination with the expression construct for SENP1 or
equivalent amount of empty parent vector. Cells were treated post-
transfection with 1028 M 1,25D at defined time points followed by
isolation of total RNA using an Aurum Total RNA Mini Kit (Bio-
Rad, Hercules, CA). DNase treated RNA (2 mg) was then reverse
transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) and
the resultant cDNA employed in PCR reactions containing 10 mL
iQ SYBR Green Supermix (Bio-Rad), 1 mL primers, 2 mL of
cDNA template sample, and molecular grade water to a final
reaction volume of 20ml. Real-time PCR was performed on the
human CYP24A1 gene using 59-CAGCGAACTGAA-
CAAATGGTCG-39 and 59-TCTCTTCTCATACAACACGA-
GGCAG-39 primers (58 bp product). Reactions were performed
in 96-well PCR plates and read on a Bio-Rad iCycler iQ Real-
Time PCR detection system or an ABI 7500 Fast instrument. Data
were analyzed using the comparative Ct method as a means of
relative quantitation, normalized to an endogenous reference
(GAPDH cDNA) and relative to a calibrator (normalized Ct value
obtained from vehicle-treated cells) and expressed as 22DDCt
according to Applied Biosystems User Bulletin 2: Rev B, ‘‘Relative
Quantitation of Gene Expression.’’
To evaluate how depletion of endogenous SENP1 may impact
upon expression of the human CYP24A1 and TRPV6 genes, Caco-
2 cells were seeded in 6-well plates at 86104 cells/well and
transfected using DharmaFECT1 (Thermo Scientific) following
manufacturer’s instructions with siRNA specific for SENP1 (ON-
TARGETplus SMARTpool L-006357-00-0005), or an non-
targeting siRNA pool (D-001810-10-05). After incubation in
transfection mix for 48 hours, cells were allowed to recover in
fresh media before addition of media supplemented with 1028 M
1,25D or vehicle control for a period of 24 hours. Following
ligand/vehicle treatments, cells were then harvested and total
RNA and protein extracted for analysis. cDNA was generated as
described above and PCR performed using the following gene
specific primers;
CYP24A1 (381 bp product).
59-CTACCGCAAAGAAGGCTACG-39
59-TTGGTGTTGAGGCTCTTGTG-39
HPRT (350 bp product).
59-GACCAGTCAACAGGGGACAT-39
59-TAGCTTGCGACCTTGACCAT-39
SENP1 (321 bp product).
59-GGCTGGTTATCAGGCAGTG-39
59-CGGAAGTATGGCATGTGTTG-39.
The resulting PCR products were visualized through electro-
phoresis using a 1% agarose gel containing 0.2% ethidium
bromide. Analysis of expression through real-time PCR approach-
es for cDNA obtained from siRNA treated samples was
accomplished on a Roche Light Cycler 480 using Real Time
assay probes specific for human CYP24A1 (assay ID: 114955),
TRPV6 (assay ID: 110452), SENP1 (assay ID: 108243) with HPRT
(assay ID: 102079) representing the endogenous reference gene.
Data was analyzed using Advanced Relative Quantification
Software (Roche). Extracted protein samples from each treatment
group were subjected to immunoblotting as described above.
Cell-based SUMOylation Assays
Detection of SUMO-modified VDR was performed as previ-
ously described [21]. Briefly, HEK293 cells were seeded in 60 mm
dishes and transfected with the appropriate construct expressing
V5-VDR (2mg), His-SUMO2 (2mg), UBC9 (1mg) Flag-SENP1 or 2
(1mg) or parent vector control. At 48 hours post transfection, cells
were harvested and the resulting cell pellets resuspended in ice-
cold RIPA buffer and subject to sonication. 20ml of V5 agarose
beads (Abcam) was added to 1 mg of the resulting cleared cell
lysate diluted with SUMO-IP buffer. After overnight incubation at
SENPs as Modulators of VDR Activity
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4uC and washing (thrice) with SUMO-IP buffer, samples were
then resuspended in 3X reducing agent/LDS sampling buffer.
After heating at 100uC for 5 minutes followed by centrifugation,
the eluted proteins were then analyzed through western blotting.
Results
SENPs Interact with VDR and RXRa and Enhance their
Ligand-induced Activation
In order to ascertain if reversible SUMOylation is an integral
process to their mechanisms of transactivation, we subjected a
select group of nuclear receptors to a functional screen in which
we assessed the impact of SENP1 co-expression upon their ligand-
induced activation. The nuclear receptors under evaluation (VDR,
RXRa, PPARc, LXRa and FXR) were represented by hybrid
constructs consisting of their respective ligand binding domain
(LBD) fused to the Gal4 DNA binding domain (DBD). Fig. 1A
reveals that SENP1 elicits the most striking effects upon the
liganded activities of the VDR and RXRa constructs and
increased their transcriptional responses to cognate ligand
approximately 3 and 19-fold respectively. In contrast SENP1 co-
expression appears to have little impact upon the transactivations
of LXRa and PPARc by their respective cognate ligands above
that obtained with the empty vector control. It is noted that both
the basal and liganded activities of FXR are increased through the
presence of SENP1 which although results in a more modest
overall fold increase (X 1.4) in transactivation to those observed for
VDR and RXRa, does suggest that this receptor may be subject to
modulation through SUMO-related events. In focusing upon their
potential role as regulators of the vitamin D pathway, we assessed
if SENP1 and also SENP2 can directly interact with VDR. Fig. 2A
depicts a mammalian two hybrid experiment in which ‘prey’
constructs encoding the LBD of VDR were paired with ‘bait’
representing SENP1 or SENP2. The data reveal that VDR can
associate with the tested SENPs in a manner that would appear to
be dependent upon the presence of ligand. Based upon the
absolute values of the luciferase signal generated, VDR exhibited
highest affinity for SENP1, although the relative fold increase in
reporter activity that resulted from the association with receptor
was comparable for both SENP isoforms.
We also utilized a ‘pull-down’ methodology to determine if
IVTT generated SENP1 and SENP2 have the capacity to interact
with a GST-hVDR fusion protein. Fig. 2B indicates that while
radiolabeled SENP proteins exhibit no association with the GST
control (lanes 3 & 4), both SENP1 (lanes 5 & 6) and SENP2 (lanes
7 & 8) are able to interact with VDR. In contrast to data obtained
in Figs. 2A and to the clear hormone-dependent nature of the
interaction exhibited between VDR and its RXRa binding
partner employed as a positive control (compare lanes 9 & 10)
we observe that in the context of the in vitro assay, associations
between VDR and SENP1 (lanes 5 & 6) and SENP2 (lanes 7 & 8)
appear to occur with equal intensity in both vehicle control and
1,25D treated samples.
SENPs Regulate the Activities of VDR in a Cell-specific
Fashion
Given that the data depicted in Figs. 1, 2A and 2B were
obtained with receptor constructs that encode the LBD of VDR,
we then determined the impact of SENPs upon the transcriptional
responsiveness of the full length version of this receptor assessed in
the context of three different cell lines. In these experiments we
employed: a Gal4-response element based reporter used in
combination with hybrid constructs containing the full length
VDR and; a reporter based upon the human CYP24A1 gene
promoter to assess the ability of SENPs to modulate VDRE-
mediated activation by the VDR-RXRa heterodimer. Fig. 3
demonstrates that in HEK-293 cells, SENP1 and 2 were both able
to enhance the vitamin D signal using both the Gal4 (A) and
CYP24A1 (B) reporter systems. Immunoblot analysis of cellular
lysates produced in Fig. 3A verifies that the increase in
transcriptional potency is not a consequence of altered hybrid
receptor protein levels (left middle panel) while both SENP
proteins are noted to be expressed equivalently under our
experimental conditions (right middle panel). When examined in
the context of Caco-2 colon carcinoma cells, a similar profile of co-
activation by SENP1 and SENP2 is achieved using the same Gal4
(C) and CYP24A1 (D) reporter systems. A general observation
from experiments using the Gal4 system is that the impact of
SENP upon receptor activation is even more effective when
employing constructs expressing the full length VDR protein as
compared to its LBD version. In contrast, Fig. 4 illustrates that the
effects of SENP co-expression upon the 1,25D signal are
remarkably diminished when assessed using MCF-7 breast cancer
cells. In this cell model, neither SENP1 nor SENP2 has any effect
on the transcriptional activity of VDR when examined using the
Gal4 reporter (Fig. 4A) with similar effects observed with the
CYP24A1-based system (Fig. 4B). In contrast, the RXRa-
mediated signal was observed to be profoundly enhanced through
SENP co-expression in these cells, with SENP1 eliciting the most
potent effect upon activation of this receptor (Fig. 4A).
Figure 1. SENP1 selectively potentiates the transcriptional
activities of VDR and RXRa. HEK-293 cells were transfected with the
pFLUC reporter vector in combination with the appropriate pCMVBD-
based expression vector for each Gal4-nuclear receptor (LBD) hybrid
protein under evaluation. Where indicated, cells also received the
SENP1 expression plasmid, pFLAG-CMV-SENP1 (200 ng), or an equiva-
lent amount of parent vector (minus SENP1 insert) as control. The total
amount of DNA in each transfection was kept at a constant value
through inclusion of the appropriate amount of empty expression
vector. Treated cells were dosed with the appropriate cognate ligand or
vehicle control for a period of 24 hours before measurement of
luciferase activity. All ligands were used at a concentration of 1026 M,
except 1,25D (1028 M). After normalization for transfection efficiency
based on the activity of the pRL-TK control, results were expressed as
relative luciferase units per well. The fold-stimulation (ratio of activity in
the presence:absence of ligand) is indicated above each set of bars.
Data represents analysis of at least three independent experiments with
each treatment run in triplicate (n= 3) mean 6 SD; where ns=p$0.05,
** p = 0.001–0.01, *** p= 0.0001–0.001 and **** p,0.0001.
doi:10.1371/journal.pone.0089506.g001
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Hormone-dependent Expression of an Endogenous
Vitamin D Target Gene is Significantly Enhanced by
SENP1
To assess the effects of SENP1 upon an endogenous vitamin D
target gene, we next employed real time PCR analysis to evaluate
the impact of SENP1 over-expression within Caco-2 cells upon the
transcriptional response of the CYP24A1 gene to 1,25D. The data
depicted in Fig. 5 demonstrate that exposure of Caco-2 cells to
1,25D (10 nM) for a 24 hour period will typically result in a 50-
fold increase in the detectable levels of CYP24A1 mRNA when
compared to vehicle treated cells. Remarkably, for Caco-2 cells
that prior received the SENP1 expression vector, the 1,25D-driven
induction of CYP24A1 mRNA became further increased to 143-
fold, signifying an approximate increase of 300% in the hormone
responsiveness of this vitamin D target through the addition of
exogenous SENP1. Comparable results are observed for similarly-
treated Caco-2 cells exposed to 1,25D for a 4 hour time period
(data not shown).
Knockdown of Endogenous SENP1 will Diminish the
Ability of 1,25D to Induce CYP24A1 Gene Expression
As our previous experiments relate the impact of SENP1
overexpression, we next probed how the endogenous 1,25D
response would be affected through depletion of cellular SENP1
through application of siRNA. Fig. 6A visually confirms that a
gene-specific siRNA against SENP1 will result in a reduced mRNA
expression for this gene within Caco-2 cells with this effect
maintained following exposure to 1,25D or vehicle control.
Intriguingly when compared to the non-targeting (NT) control, a
diminished transcriptional response of the CYP24A1 gene to 1,25D
is noted within SENP1 depleted cells (second row; compare lane 4
with lane 2), an effect not related to a lower level of VDR protein
as confirmed through immunoblotting of corresponding lysate
samples (data not shown). Q-PCR analysis confirms that the gene-
specific siRNA will achieve a ‘knockdown’ of SENP1 mRNA
expression in the 1,25D treatment group by approximately 80%
(Fig. 6A) and a transcriptional response of CYP24A1 that is
diminished by approximately 65% (Fig. 6C). In contrast, depletion
of cellular SENP1 has no statistically significant effect upon the
mRNA expression of TRPV6 (Fig. 6D).
SENP1 and SENP2 Reverse Modification of VDR with
SUMO2
As the functionality and SUMO-modification status of several
nuclear receptors are known to be modulated through SENP-
directed function, we performed a series of cell-based assays as
depicted in Fig. 7 to evaluate the impact of SENP overexpression
upon the SUMO status of VDR. For this purpose we utilized our
previously described cell-based assay system in which V5-VDR is
expressed in combination with components of the SUMO
conjugation pathway (2/+ SENP) and the resulting lysates then
subjected to immunoprecipitation using a V5-specific polyclonal
antibody followed by western blot analysis for the detection of V5-
VDR and its modified forms. In Fig. 7A, we verify our previous
findings that VDR is modified by SUMO2 with this event
dependent upon the co-expression of Ubc9 (compare lanes 1 and
2). The SUMOylated VDR is detected as a 72 KD band within
precipitated cell lysates through use of antibodies specific for
‘tagged’ His-SUMO2 and V5-VDR. Formation of the SUMO2
conjugated VDR is again demonstrated in Fig. 7B (lane 3),
however when this assay is performed to encompass either the
Flag-SENP1 (lane 4) or Flag-SENP2 (lane 5) expression constructs
the modified VDR is no longer detected. The lower panels
confirm expression of V5-VDR and Flag-SENP within the
corresponding treatment groups in which we note a slightly
reduced V5-VDR protein expression within those lysates that
include SENP (compare lanes 1&2 with lanes 3&4). Fig. 7C
further confirms the deSUMOylation of VDR, in this case
through SENP2 co-expression (compares lanes 1 and 2) with the
middle panel verifying the co-expression of His-SUMO2 in this
experiment. In lane 2 (middle panel) it is noted that the presence of
SENP2 results in a loss of the upper band that represents the
dimeric-SUMO2 species and a resulting predominance of the
Figure 2. Members of the SENP family directly interact with
VDR. A. Mammalian two-hybrid assay was employed to assess the
abilities of VDR to directly associate with SENP 1 or 2. CHO KI cells were
co-transfected with the pFR-LUC reporter along with the indicated
combination of bait (pCMVBD-SENP1 or 2) and prey (pCMVAD,
pCMVAD-VDRLBD) constructs. Cells were incubated with 1,25D
(1028 M), or vehicle control for a period of 24 hours before
measurement of luciferase activity. After normalization for transfection
efficiency based on the activity of the pRL-TK control, results were
expressed as relative luciferase units per well. Data represents the
average of three independent experiments run in triplicate, mean 6
S.D; where ns=,0.05, * p = 0.01–0.05, ** p = 0.001–0.01. B. Interaction
between VDR and SENP1 & 2 was monitored through GST-pulldown
assay. GST-hVDR fusion protein, or GST alone, bound to glutathione-
coated Sepharose beads were pre-incubated with 1026 M 1,25D (D
lanes) or ethanol vehicle (Et lanes) for 1 h at 22uC, followed by
incubation with 20 ml of [35S]-methionine-labeled SENP or RXRa
proteins for 1 hour at 4uC. After washing, coprecipitated SENPs or
RXRa was detected by electrophoresis of denatured bead samples
followed by autoradiography. Aliquots (5%) of all radiolabeled protein
are shown in the input lanes (1 & 2) to assess the level of SENP
synthesized in the IVTT reaction. Lanes 9 & 10 detail positive controls
employing RXRa, an established VDR-interacting protein. Data is
representative of three independent experiments.
doi:10.1371/journal.pone.0089506.g002
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single (mono) SUMO2 form, verifying the enzymatic functionality
of the expressed SENP2 protein.
Lysine 91 of VDR is a Minor SUMO Acceptor Site
In a preliminary attempt to identify which residue(s) within
VDR may be subject to modification with SUMO, we employed
site-directed mutagenesis analysis in which lysine at potential
acceptor sites within VDR identified using the SUMOplotTM
prediction tool (http://www.abgent.com.cn/doc/sumoplot/login.
asp) was replaced with arginine. As detailed within Fig. 8, the three
main potential conjugation sites (K91, K103 and K111) identified
through inspection by this and other programs do not fulfill the
yKxE criteria for a true consensus SUMO site. Each mutation
was assessed through cell-based SUMOylation assays involving
transient transfections of HEK-293 cells or Hela cells that stably
express SUMO2. All experiments depicted in Fig. 8 included
PIAS4, which we have previously reported to enhance SUMOyla-
tion of VDR in a fashion that may involve modification at more
than one site [21]. Such a possibility is confirmed in Figure 8A in
which inclusion of PIAS4 results in several SUMO-VDR species
detected at 72, 95 and 132 KD. While none of the tested mutants
exhibit a complete loss of receptor modification, we consistently
Figure 3. SENPs potentiate transactivation of the full length VDR protein. A. HEK-293 cells received pCMVBD-VDRFL that encodes Gal4DBD
fused to full length human VDR, in combination with the pFR-LUC reporter and the indicated SENP expression construct or parent vector control. The
lower panel depicts an immunoblot analysis in which combined cellular lysates from each treatment group were probed with the antibodies specific
for VDR (9A7) and b-actin. B. pSG5-hVDR that expresses full length human VDR were co-transfected into HEK-293 cells in combination with the
reporter construct pMCS-24OHase, pSG5-hRXRa and the appropriate Flag-SENP expression plasmid or parent vector control. Transfected cells were
incubated with 1,25D (1028 M) or vehicle for 24 hours before measurement of luciferase activity. The lower panel depicts immunoblot analysis of cell
lysates transfected with the pFlag-SENP1 or pFlag-SENP2 expression constructs and then probed with the Flag or b-actin specific antibodies, with
WCE representing the untransfected whole cell lysate control. The fold stimulation are expressed as means (6 SD) and results presented are the
average of three independent experiments, where n= 3 in each assay. C. Caco-2 cells were co-transfected with pCMVBD-VDRFL and pFR-LUC reporter
in combination with the appropriate SENP expression constructs or parent vector control. D. Caco-2 cells received pSG5-hVDR+pSG5-hRXRa, the
pMCS-24OHase reporter, together with the indicated SENP expression plasmid or parent vector control. Transfected cells were then incubated with
1,25D (1028 M) or vehicle control for 24 hours before measurement of luciferase activity. All depicted data represents an average of four independent
experiments with values expressed as means (6 SD) of triplicate assays (n=3) where ** p = 0.001–0.01, *** p= 0.0001 - 0.001, **** p,0.0001.
doi:10.1371/journal.pone.0089506.g003
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observe that in the context of both the HEK-293 (Fig. 8A) and
Hela (Fig. 8B) cell-based systems, the K91R mutant exhibits an
overall reduced level of modification characterized by the
disappearance of the SUMO-VDR species that migrates at
132 KD. These data intimate that residue K91 may represent a
minor SUMO2 acceptor site. We also included in this analysis the
K399R and K413R variants of VDR which represent potential
ubiquitin [23] and acetylation [24] sites respectively, so as to
determine if SUMO-modification of VDR was reliant on these
processes. The data describe these mutants to possess a similar
pattern of SUMO2 conjugation to that exhibited by wild type
VDR (Figure 8A, right panel).
We then assessed transactivation of the K91R mutant by 1,25D
in comparison to the wild type and K103R forms of VDR. Fig. 9
describes data obtained using the (A) CYP3A4 and CYP24A1
promoter constructs and the (B) Gal4-based reporter system. In
each context, we consistently observe the K91R mutant to exhibit
a higher level of transactivation compared to the intact VDR. This
is most apparent when employing the Gal4 system in which the
liganded activity of the K91R mutant is approximately 55%
greater than that of the wild type VDR, while in contrast the
responses of K103R VDR to 1,25D appear to be marginally
diminished when assessed in the context of the CYP3A4 and Gal4
systems.
Discussion
In this report we expand upon our previous findings that
SUMO-related activity can modulate the vitamin D hormonal
response and demonstrate that members of the SENP family can
interact with VDR to reverse its modification with SUMO2 in
addition to significantly potentiating its transactivation by the
1,25D ligand. The current study primarily focused on those effects
exerted by SENP1 and SENP2 as their isopeptidase activities
exhibit equal preference towards nuclear substrates modified with
any of the three SUMO isoforms [9,25]. Our experiments
excluded SENP3 and SENP5 as they are located principally
within the nucleolus and therefore their potential for interaction
with VDR likely to occur under specific biological conditions
outside the scope of this study [9,25]. We do acknowledge that a
complete appreciation of how SENPs impact upon the vitamin D
response need in future also consider the activities of SENP6 and
SENP7, which although are more modestly engaged in deconju-
gation of mono-SUMOylated proteins are localized within the
nucleoplasm and possess a specialized capacity to dissemble poly
SUMO2/3 chains [25]. This latter feature may be of relevance to
VDR which we have demonstrated may exist as a multi or poly-
SUMO2 conjugated protein as a result of the E3-ligase activities of
PIAS4 [21]. In the context of our initial screening assay we find
SENP1 to be a robust modulator of the ligand-induced
transactivation of both VDR and its RXRa heterodimeric partner.
That no comparable effects were observed for the PPARc and
LXRa constructs verifies our observations to be specific and not
an inherent feature of the Gal4-based system. SUMOylation of the
ligand binding domains of PPARc and LXRa has been shown to
be pivotal to their transrepression function [14,16] and therefore
SENP1 co-expression may not impact upon their transactivation
by ligand when assessed through this assay. We confirm the effects
of SENP1 using gene-reporter constructs and also in the context of
the endogenous CYP24A1 vitamin D target gene as evidenced
Figure 4. Transcriptional activities of VDR and RXRa in MCF-7
cells are differentially modulated by SENPs. A. MCF-7 cells were
seeded under conditions defined in methods and received the
indicated SENP expression construct or corresponding parent vector
control in combination with the pFLUC reporter and pCMVBD-VDRFL or
pCMVBD- RXRaFL. B. pSG5-hVDR and pSG5-hRXRa were co-transfected
into MCF-7 cells in combination with the pMCS-24OHase reporter and
appropriate Flag-SENP expression plasmid or parent vector control.
Cells were then dosed for 24 hours with the 1,25D (1028 M) or 9-cis RA
(1026 M) cognate ligands or vehicle control where indicated. The fold-
stimulation (ratio of activity in the presence:absence of ligand) is
indicated above each set of bars. The results are presented as means (6
SD) from three independent experiments with each data point
measured in triplicate (n=3) where ns p$0.05, ** p= 0.001–0.01, ****
p,0.0001.
doi:10.1371/journal.pone.0089506.g004
Figure 5. SENP1 potentiates the hormone responsiveness of an
endogenous vitamin D target gene. Caco-2 cells were plated as
described in methods and co-transfected with pSG5hVDR and, where
indicated, pFLAG-CMV-SENP1 or corresponding parent vector control.
Following incubation for a period of 24 hours with 1,25D (10 nM) or
vehicle control, total RNA was isolated from cells, converted to cDNA
and real time PCR analysis performed. The fold-stimulation of CYP24A1
mRNA expression achieved through the presence of 1,25D is indicated
above the black bars. The depicted data represents an average of three
independent experiments with each data point a means (6 SD) of
triplicate assays (n= 3) and **** p,0.0001.
doi:10.1371/journal.pone.0089506.g005
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through its profoundly enhanced response to hormone following
SENP1 over-expression. Conversely, depletion of cellular SENP1
significantly diminished mRNA expression of CYP24A1 but had
little effect upon TRPV6. Such differing responses of these vitamin
D target genes may be reflective of distinct SUMO-modification
patterns for VDR and/or its co-regulatory complexes associated
with differing chromatin contexts and warrant future consider-
ation that SENP-mediated modulation of the vitamin D response
may be gene-specific. Indeed, if SENPs do exert their most potent
effects upon regulation of CYP24A1, then their enhancement of the
expression of this gene and its associated catabolism of the 1,25D
ligand may have implications as to SENP involvement in vitamin
D resistance. SENP1 expression levels have been demonstrated to
be elevated during prostate pathogenesis [26–27] while those of
CYP24A1 are increased in cancers of the prostate, colon, ovary,
and lung, a number of which are known to be insensitive to the
growth-regulatory effects of vitamin D [28,29]. It is also important
to consider that SENP1 and SENP2 may exhibit a degree of
functional redundancy and so determination of the true extent of
their influence upon the VDR-mediated signaling will warrant
simultaneous knockdown of more than one SENP family member.
Our previous work has identified that the modification of VDR
with SUMO2 is significantly enhanced through the E3-ligase
activity of PIAS4 which also serves to repress the 1,25D
transcriptional signal [21]. When taken in consideration with the
current data, we propose a working model in which the principal
effect of VDR SUMOylation is to increase the receptor population
bound to co-repressor in a manner similar to the reported
recruitment of NCoR1 by the SUMO1-conjugated form of
PPARa [30]. Within the context of the VDR-RXR heterodimeric
complex, binding of ligand would then result in conformational
changes that facilitate recruitment of SENP(s) whose associated
activities result in the release of co-repressors and/or the assembly
of co-activator complexes. While the hormone-dependent inter-
actions exhibited in our mammalian two hybrid system support
such a role for SENPs, our pull-down data do not clearly indicate
an influence of 1,25D upon formation of the VDR-SENP
complex. It is possible that when assessed within the context of
an intact cellular milieu, such as that represented by the two
hybrid system, binding of 1,25D by VDR may lead to the
recruitment of other proteins which help further stabilize
interactions between SENP and receptor that are not achieved
in the pull-down system. Such a scenario would suggest that an
interacting SENP may also form contacts with one or more
components associated with the liganded VDR or indeed the
RXR heteropartner. Indeed, while we demonstrate that SENPs
can deconjugate the SUMO2-modified VDR, it is conceivable
that their ability to enhance the 1,25D transcriptional response
may also be partially attributable to the deSUMOylation of other
proteins within VDR-recruited proteins in a fashion similar to the
enhanced responsiveness of AR to ligand that results from
targeting of HDAC1 by SENP1 [31]. Such a mechanism involving
VDR-associated proteins is supported by the apparent cell-line
specific effects noted in this study in which SENP co-expression
has little impact upon the vitamin D signal when assessed in MCF-
Figure 6. Depletion of endogenous SENP1 results in a
diminished induction of CYP24A mRNA expression by 1,25D.
Caco-2 cells were seeded and co-transfected with 100nM Dharmafect
SENP1 siRNA or Non-Targeting (NT) control or as described in methods.
Cells were then treated with vehicle or 1,25D (1028 M) for 24 hours
before RNA/protein extraction and subsequent analysis through RT-
PCR/qRT-PCR and immunoblotting. A. RT-PCR depicting gene specific
PCR products obtained from Caco-2 cells transfected with non-
targeting (NT) and SENP1-specific siRNAs and subsequently treated
with 1,25D or vehicle control. The lower panels describe Q-PCR analysis
of the impact of NT and SENP1-specific siRNAs upon the mRNA
expression within 1,25D treated Caco-2 cells of (B) SENP1, (C) CYP24A1
and (D) TRPV6. The experiment depicted in A is representative of three
independent experiments while B, C and D describe the average of
three independent experiments where each data point represents the
means (6 SD) of triplicate assays (n= 3) and where ns p$0.05, **
p = 0.001–0.01, **** p,0.0001.
doi:10.1371/journal.pone.0089506.g006
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7 breast cancer cells while under the same experimental conditions
the RXRa transcriptional response is profoundly enhanced. Such
findings may again reflect distinct cellular/tissue specific profiles of
SUMO-substrates among VDR co-regulator proteins and/or
varied patterns of SUMOylation associated with the receptor
itself. This is an intriguing scenario that may provide a critical
Figure 7. SENPs facilitate deSUMOylation of VDR. Depicted are cell-based SUMOylation assays performed as described in materials and
methods using the following experimental conditions: A. HEK-293 cells received expression constructs for V5-VDR, His-SUMO2 and UBC9 or parent
control. Cell lysates from each treatment group were incubated with V5-agarose beads and the resulting precipitated material subjected to western
blot analysis with antibodies specific for 6x His (upper panel) or V5 (lower panel) epitope tags. The arrowheads indicate unconjugated and SUMO2-
modified versions of V5-VDR. B. Where indicated, cells were co-transfected with V5-VDR, His-SUMO2, UBC-9 in combination with FLAG-SENP-1 or
FLAG-SENP-2 with (-) denoting inclusion of appropriate parent vector control. The upper panel describes detection of SUMO2-conjugated VDR within
precipitated lysates with expression of V5-VDR and Flag-SENP within the appropriate treatment groups confirmed in the lower panel. C. Cells received
the indicated combination of V5-VDR, His-SUMO2, UBC-9 along and FLAG-SENP-2 or parent vector control. Upper panel depicts detection of SUMO2
conjugated VDR and reversal of this modification by SENP2. Lower panels confirm the expression status of unconjugated SUMO2.
doi:10.1371/journal.pone.0089506.g007
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contributory mechanism underlying the pleiotropic effects of
vitamin D and the variable sensitivity to VDR ligands exhibited
between different cell types or disease states based upon altering
SUMOylation of receptor/accessory proteins. In addition, our
previous report observed that over-expression of PIAS4, in
addition to enhancing SUMOylation of VDR, also increased the
protein levels of this receptor [21]. In this current study we note
that co-expression of SENP1 or SENP2 is associated with a
reduced level of VDR protein and so it will be intriguing to
establish if a functional link exists between the SUMOylation
status of VDR and receptor stability/degradation. It is possible
that SUMOylation may inhibit the VDR-mediated signal through
impeding receptor clearance from the promoters of target genes at
the later stages of the VDR transcriptional ‘life cycle’ [32] with this
then reversed through SENP-directed activity.
In silico screening reveals that while VDR lacks a true SUMO
consensus sequence, this receptor does possess a number of
potential type II (non-consensus) acceptor sites that include K91,
K103 and K111, all located within a region previously defined as a
C-terminal extension (CTE) of the core zinc finger DNA binding
domain [33]. While our initial analysis reveal none of these
residues represent the predominant contributor to VDR SUMOy-
lation, our data do describe K91 as a minor acceptor site as
implicated though the loss of the higher migrating SUMO-VDR
species that typically form in the presence of PIAS4. K91, along
with E92 are components of the T-box located within the CTE of
VDR and are critical for mediating dimerization with RXR and
binding of the heterocomplex to DNA [34,35]. A previous report
described replacement of K91 and E92 with asparagine and
glutamine respectively that result in an almost complete reduction
in transcriptional activity [35]. Our present study details that the
more conservative replacement of K91 with arginine will avoid
such a dramatic loss of activity, likely due to the mutant variant
retaining the capacity to form salt bridges with the D-box of RXR.
The loss of SUMOylation that accompanies the K91R change is
accompanied by an increased level of VDR transactivation in
response to cognate ligand, thus supporting our hypothesis that
this post-translational modification will exert a repressive function
upon VDR. In the specific case of K91, such effects of
SUMOylation are possibly mediated through impeding formation
of the VDR-RXR heterodimer and its association with DNA. In
contrast, in substituting K103 with arginine we generated a VDR
variant that exhibits a modest decrease in ligand responsiveness,
particularly when assessed in the context of the CYP3A4 promoter
and Gal4 reporter systems. These findings correlate with the
findings of Hsieh and co-workers in which the K103A and K111A
mutant forms of VDR exhibited an even greater loss in
transcriptional potency, reflecting their potential role as contact
Figure 8. Identification of a possible SUMO acceptor site within VDR. Top: Predicted SUMO sites within VDR using the SUMOplotTM tool. A.
Depicted are HEK-293 based SUMOylation assays of VDR mutant variants containing K to R substitutions at potential SUMO acceptor sites present
within the C-terminal extension (left panel) and ubiquitin (K399R) and acetylation sites (middle panel). The asterisks denote SUMO2 modified VDR
forms migrating at 72, 95 and 135 KD. B. SUMOylation assay of the wild type and K91R forms of VDR using HeLa cells that stably express SUMO2. All
experiments included the expression construct for UBC9. Lower panels to both A and B confirm the equivalent expression of each mutant and
individual components included in the assay.
doi:10.1371/journal.pone.0089506.g008
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sites for transcriptional co-activators or basal transcription factors
[33]. It is an on-going program of research in our laboratory to
probe VDR for the remaining cryptic SUMO acceptor sites
utilizing additional methodologies to creating single site mutants.
Throughout this study we also consistently observed that
SENP1 potently enhanced the ligand-induced activation of
RXRa. It has been reported that K108, located within the AF-1
region of RXRa, is an acceptor site for SUMO1 and that reversal
of this modification by SUSP1 (SENP6) leads to an enhanced
receptor activity [36]. The same study also observed that SENP1
was unable to deconjugate the SUMO1-modified RXRa and had
no detectable effect upon its transcriptional activation. While we
also note enhancement of RXRa activity by SENP6 to levels
comparable to that reported by Choi and co-workers (data not
shown), we consistently find that its potentiating effects are modest
in comparison to those elicited through SENP1 when evaluated in
the context of the Gal4 system and also RXRE-based reporter
assays which employ the intact native form of RXRa (data not
shown). We are uncertain of the exact reason(s) that underlie the
discrepancy between our findings with respect to the actions of
SENP1 on RXRa, particularly when our two studies have
employed similar methodologies and cell types. It should also be
noted that the RXRa LBD construct utilized in our initial screen
(Fig. 1) encompasses residues 197 to 462 and so excludes K108,
but still exhibits a profound capacity to be stimulated by SENP1.
These data suggest that RXRa may contain SUMO acceptor sites
that are additional to K108, although an alternative explanation is
again that SENP1 may be targeting deSUMOylation of an RXRa
protein co-factor.
In total, our novel data reveal that the process of reversible
SUMOylation to represent a mechanism that may enable ‘fine-
tuning’ of the transcriptional activities of the VDR/RXRa
heterodimer in a cell and gene specific context and involve
modification of VDR at one than one site. Additional character-
ization of this process and its modulation with respect to VDR and
RXR in addition to those protein co-factors recruited to this
heterodimeric complex will be critical to understanding the
molecular basis that underlies the cell, tissue and promoter-
specific responses to the endocrine and dietary-derived ligands of
VDR.
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